Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1587-1591

  Ho, Cheryl ^a   Davies, Angela M ^b   Sangha, Randeep S ^d   Lau, Derick ^c   Lara, Primo ^c   Chew, Helen K ^c   Beckett, Laurel ^c   Mack, Philip C ^c   Riess, Jonathan W ^c   Gandara, David R ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Novocure GmbH   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

Nab paclitaxel; Nanoparticle albumin bound paclitaxel; Non small cell lung cancer; Pemetrexed; Phase II

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CELLULITIS; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; VOMITING;

AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 84888637003     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0024-y     Document Type: Article

References (19)

1. American Cancer Society (2013) Cancer facts and figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf. Accessed Jul 2013
2. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543-3551
3. Mok TS, Wu Y, Thongprasert S, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
4. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432-1440
5. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362
6. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[comment]. J Clin Oncol 18:2095-2103
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
8. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
9. Eli Lilly and Company (2012) ALIMTA full prescribing information. http://pi.lilly.com/us/alimta-pi.pdf. Accessed Jul 2013
10. Celgene Corporation (2012) ABRAXANE full prescribing information http://www.abraxane.com/downloads/Abraxane-PrescribingInformation.pdf. Accessed Jul 2013
11. Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055-2062
12. Teicher BA, Alvarez E, Liu P et al (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 26:55-62
13. Teicher BA, Chen V, Shih C et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023
14. Kano Y, Akutsu M, Tsunoda S et al (2004) Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother Pharmacol 54:505-513
15. US Department of Health and Human Services (2003) Common terminology criteria for adverse events (CTCAE) version 3.0. National Institutes of Health, National Cancer Institute
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92:205-216
17. Stathopoulos GP, Dimitroulis J, Toubis M et al (2007) Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Lung Cancer 57:66-71
18. Kosmidis P, Mylonakis N, Skarlos D et al (2000) Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Ann Oncol 11:799-805
19. Hanauske AR, Dumez H, Piccart M et al (2009) Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs 27:356-365